The PNP Technology
Publications
Zhang Y, Parker WB, Sorscher EJ, Ealick SE (2005) PNP anticancer gene therapy. Current Topics in Medicinal Chemistry 5: 1259-1274.
Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AEA, Silamkoti AV, Fowler AT, Waud WR, Secrist JA III (2005) Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucleosides, Nucleotides, and Nucleic Acids 24: 387-392.
Silamkoti AV, Allan PW, Hassan AE, Fowler AT, Sorscher EJ, Parker WB, Secrist JA 3rd (2005) Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer. Nucleosides, Nucleotides, and Nucleic Acids 24: 881-885.
Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR (2005) Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum Gene Ther. 16: 339-47.
Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, and Sorscher EJ (2004) Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase Gene. Cancer Res. 64: 6610-6615.
Curlee KV, Parker WB, and Sorscher EJ (2004) Tumor sensitization to purine analogs by E. coli PNP. Methods Mol. Med. 90: 223-246.
Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, and Ealick SE (2003) Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem. Biol. 10: 1173-1181.
Hassan AE, Parker WB, Allan PW, Montgomery JA, and Secrist JA 3rd. (2003) Selective metalation of 6-methylpurines: synthesis of 6-fluoromethylpurines and related nucleosides. Nucleosides Nucleotides Nucleic Acids 22: 747-749.
Bennett EM, Li C, Allan PW, Parker WB, and Ealick SE (2003) Structural basis for substrate specificity of Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 278: 47110-47118.
Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, and Sorscher EJ (2003) A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304: 1280-1284.
Parker WB, Allan PW, Hassan AEA, Secrist JA III, Sorscher EJ, and Waud WR (2003) Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Therapy 10: 23-29.
Hassan AEA, Shortnacy-Fowler AT, Montgomery JA, and Secrist JA III (2000) A convenient synthesis of 2'-deoxy-2-fluoroadenosine; a potential prodrug for suicide gene therapy. Nucleosides, Nucleotides, and Nucleic Acids 19: 559-565.
Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, and Sorscher EJ (2000) In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Therapy 7: 1738-1743.
Hassan AE, Abou-Elkair RA, Montgomery JA, and Secrist JA III (2000) Convenient syntheses of 6-methylpurine and related nucleosides. Nucleosides, Nucleotides, and Nucleic Acids 19:1123-1134.
Secrist JA III, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, and Sorscher EJ (1999). Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18: 745-757.
Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, and Bennett LL Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55: 1673-1681.
Hughes BW, King SA, Allan PW, Parker WB, and Sorscher EJ (1998) Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J. Biol. Chem. 273: 2322-2328.
Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, and Sorscher EJ (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Human Gene Therapy 8: 1637-1644.
Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RI Jr, Parker WB, and Sorscher EJ (1995) Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55: 3339-3345.
Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, and Parker WB (1994) Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Therapy 1: 233-238.